Henderson Molly's Form 4 filing
Phathom Pharmaceuticals, Inc.PHAT · filed Nov 3, 2023
- Accession no.
- 0001209191-23-054355
- Filed
- Nov 3, 2023
- Trade date
- Nov 1, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $110.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Henderson MollyCIK 0001363812 | Officer (CFO and CBO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 1, 2023 | Common Stock | AGrant or awardAcquired | +22,500 | $0.00 | $0 | 117,680 | Direct | |
| Nov 1, 2023 | Common Stock | SSaleDisposed | −811 | $7.80F2 | −$6,325.8 | 116,869 | Direct | |
| Nov 1, 2023 | Common Stock | SSaleDisposed | −11,681 | $8.95F2 | −$104,544.95 | 105,188 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents shares sold to satisfy tax withholding obligations upon the settlement of performance stock units.
Referenced by the price of 2 transactions in Table I.